TORL-1-23, a CLDN6–focused antibody-drug conjugate (ADC), generated responses and was nicely tolerated in closely pretreated, CLDN6-positive superior strong tumors, together with platinum-resistant ovarian most cancers, in keeping with information from the part 1 TORL-123-001 trial, introduced on the 2024 ESMO Congress.
In line with the Nationwide Most cancers Institute, an ADC is a substance consisting of a monoclonal antibody that binds to particular proteins or receptors inside most cancers cells, which enter the cell to kill it with out harming different cells.
Research Highlights:
- TORL-1-23 demonstrated promising efficacy in closely pretreated sufferers with CLDN6-positive superior strong tumors, together with platinum-resistant ovarian most cancers.
- The antibody-drug conjugate was nicely tolerated with a good security profile, and the maximum-tolerated dose had not but been reached.
- Responses noticed with TORL-1-23 have been sturdy, suggesting the potential for long-lasting advantages.
- TORL-1-23’s focusing on of CLDN6, a protein overexpressed in varied cancers, represents a focused method to most cancers remedy.
Findings confirmed that amongst all efficacy-evaluable sufferers, 19 sufferers handled with TORL-1-23 at doses of lower than 2.4 milligrams (mg) per kilogram (kg), the general response charge (ORR; the share of sufferers with a constructive response to remedy) was 26%, which completely comprised partial responses (PRs; a lower in tumor dimension or the extent of most cancers within the physique); 42% of sufferers had secure illness (SD; most cancers that’s neither rising nor reducing in severity or extent) and 32% of sufferers had progressive illness (PD; most cancers that spreads, grows or worsens). At a dose of two.4 mg/kg (19 sufferers), the ORR was 42% with all responders reaching a PR; the charges of SD and PD have been 47% and 11%, respectively. At a dose of three mg/kg (26 sufferers), the ORR was 31%, together with a whole response (the disappearance of all indicators of most cancers from remedy) charge of 4% and a PR charge of 27%; the respective SD and PD charges have been 46% and 23%.
In sufferers with CLDN6-positive platinum-resistant ovarian most cancers, the ORRs have been 30% at doses lower than 2.4 mg/kg, 50% (4 out of 8 sufferers) on the 2.4 mg/kg dose, and 42% (5 out of 12 sufferers) on the 3 mg/kg dose.
Lead examine creator Dr. Gottfried E. Konecny stated the ADC was nicely tolerated with a good security profile. The chance of neutropenia (decrease than regular ranges of neutrophils, a sort of white blood cell) was mitigated by prophylactic pegfilgrastim (a drugs used to stop neutropenia), and the maximum-tolerated dose (MTD) of TORL-1-23 had not but been reached.
“The promising exercise was confirmed as being sturdy and deep. … [There were encouraging data for] all sufferers handled in dose escalation, significantly in [patients with] ovarian most cancers handled at 2.4 mg/kg and three mg/kg,” Konecny stated throughout a presentation of the information. He’s the lead clinician for gynecologic oncology within the Division of Drugs on the College of California, Los Angeles.
CLDN6 is expressed at excessive ranges in quite a lot of cancers and has little to no expression in regular tissues, Konecny defined throughout the presentation.
TORL-123-001 Design and Enrollment
The part 1, first-in-human examine enrolled sufferers a minimum of 18 years of age with superior strong tumors who had measurable illness, an ECOG efficiency standing of 0 or 1 (absolutely lively or restricted strenuous exercise) and ample organ operate.
TORL-1-23 is being evaluated at 11 completely different dose ranges starting from 0.2 mg/kg to three.6 mg/kg. At dose degree 9 (3 mg/kg), dose degree 10 (4.0 mg/kg), and dose degree 11 (3.6 mg/kg), prophylactic pegfilgrastim can also be being administered at a dose of a minimum of 3 mg/kg.
The dose-expansion portion of the examine consists of sufferers with CLDN6-positive platinum-resistant ovarian most cancers, CLDN6-positive refractory non-small cell lung most cancers (NSCLC), different CLDN6-positive refractory cancers, and CLDN6-low refractory cancers. Inside every of these teams, roughly 10 to twenty sufferers are being handled at each 2.4 mg/kg and three mg/kg.
The first targets of the examine are security, tolerability, dose-limiting toxicities and figuring out the MTD and really useful part 2 dose.
Amongst sufferers enrolled within the dose-escalation portion of the examine (51 sufferers), the median age was 61 years. Tumor sorts included ovarian (36 sufferers), testicular (4 sufferers), endometrial (7 sufferers), NSCLC (2 sufferers) and different (2 sufferers). This affected person inhabitants obtained a median of 4 prior strains of remedy. Thirty-eight sufferers had CLDN6-positive illness per immunohistochemistry (IHC).
In dose enlargement (30 sufferers), the median age was 65 years. Tumor sorts included ovarian (14 sufferers), testicular (1 affected person), endometrial (6 sufferers), NSCLC (6 sufferers) and different (3 sufferers). Sufferers obtained a median of three prior strains of remedy. Twenty-seven sufferers had CLDN6-positive illness per IHC.
Extra Efficacy and Security Knowledge
In sufferers with platinum-resistant ovarian most cancers, the median period of response was roughly 22 weeks for these handled with the two.4-mg/kg dose and roughly 30 weeks for these handled on the 3-mg/kg dose together with prophylactic pegfilgrastim.
Security information from dose enlargement confirmed that on the 2.4-mg/kg dose (16 sufferers), the most typical negative effects included anemia (any severity, 25%; extreme or worse, 0%), neutropenia (31%; 19%), nausea (67%; 0%), constipation (6%; 0%), diarrhea (25%; 6%), vomiting (25%; 0%), fatigue (56%; 19%), arthralgia (joint ache or soreness; 31%; 0%), myalgia (muscle ache; 19%; 6%), neuropathy (nerve harm; 25%; 0%) and alopecia (hair loss; 56%; 0%).
On the 3.0-mg/kg dose (14 sufferers), probably the most frequent negative effects consisted of anemia (any severity, 29%; grade ≥3, 0%), neutropenia (7%; 7%), nausea (64%; 0%), constipation (29%; 0%), diarrhea (21%; 0%), vomiting (21%; 0%), fatigue (79%; 14%), arthralgia (43%; 0%), myalgia (21%; 0%), neuropathy (57%; 0%) and alopecia (69%; 0%).
“There’s a registrational part 2 examine being initiated globally in CLDN6-positive platinum-resistant [ovarian cancer], and the molecule is underneath additional analysis in different CLDN6-positive cancers, together with NSCLC,” Konecny concluded.
For extra information on most cancers updates, analysis and training, don’t neglect to subscribe to CURE®’s newsletters right here.
